drugset / Trial / NCT02838316
Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the safety of Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) during the 12 months following treatment of tongue dysphagia in male and female patients who have undergone surgery and/or chemo- and/or radiotherapy for squamous cell cancer of the oropharynx.
Timeline
- Start
- 2017-05-24
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMDC-GIR | Cell therapy | 1.5e+08 cells | Intramuscular |
| Subject | AMDC-GIR | Cell therapy | 3e+08 cells | Intramuscular |